Xenetic Biosciences (NASDAQ:XBIO) Releases Earnings Results, Meets Estimates

Xenetic Biosciences (NASDAQ:XBIO) announced its earnings results on Tuesday. The company reported ($0.83) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.83), Zacks reports. Xenetic Biosciences had a negative return on equity of 43.40% and a negative net margin of 182.99%. The firm had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.54 million.

Xenetic Biosciences Price Performance

Shares of NASDAQ XBIO traded down $0.14 during midday trading on Thursday, reaching $3.15. The company’s stock had a trading volume of 59,989 shares, compared to its average volume of 7,299. Xenetic Biosciences has a 12-month low of $2.78 and a 12-month high of $5.97. The firm has a 50 day moving average price of $3.98 and a 200-day moving average price of $3.98. The stock has a market capitalization of $4.85 million, a P/E ratio of -1.08 and a beta of 2.29.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.